Evidence map›Paper›PMID 30782037›Full record

ArticleJournal of drug targeting2019

Free radical-mediated targeting and immobilization of coupled payloads.

Christopher J Lowe, Emily T DiMartini, Keana R Mirmajlesi, Adam J Gormley, David I Shreiber

Abstract read
In one paragraph

Article in Journal of drug targeting, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Christopher J Lowea Department of Biomedical Engineering, Rutgers, The State University of New Jersey , Piscataway , NJ , USA.
Emily T DiMartinia Department of Biomedical Engineering, Rutgers, The State University of New Jersey , Piscataway , NJ , USA.ORCID 0000-0003-0239-4819
Keana R Mirmajlesia Department of Biomedical Engineering, Rutgers, The State University of New Jersey , Piscataway , NJ , USA.ORCID 0000-0002-2503-1108
Adam J Gormleya Department of Biomedical Engineering, Rutgers, The State University of New Jersey , Piscataway , NJ , USA.ORCID 0000-0002-2884-725X
David I Shreibera Department of Biomedical Engineering, Rutgers, The State University of New Jersey , Piscataway , NJ , USA.ORCID 0000-0001-8248-419X

Funding

UMDNJ TRAINING GRANT IN BIOTECHNOLOGYT32GM008339 · NIGMS · RUTGERS THE ST UNIV OF NJ NEW BRUNSWICK · PI YARMUSH, MARTIN L · 1989 to 2019
$6.1M
NIGMS NIH HHS T32 GM008339
6 · The paper itself

Abstract

Targeted drug delivery is a promising approach to enhance the accumulation of therapies in diseased tissues while limiting off-site effects. Ligand-receptor interactions are traditionally identified to deliver therapies, and although specific, this can be costly and often suffers from limited sensitivity. An emerging approach is to target intermediary species that modulate disease progression. Here, we propose novel methods of targeting therapies by using native free radicals as a homing signal. Elevated concentrations of free radicals are a characteristic comorbidity of many different diseases. In polymer chemistry, free radicals are frequently used to initiate crosslinking reactions. We proposed that free radicals elevated in injury sites are capable of inducing crosslinking of acrylate groups on polymer chains. Coupling payloads to the polymer then allow for specific targeting of therapies to areas with elevated free radicals. We demonstrate

Indexed as

Drug Delivery SystemsAcrylatesAnimalsCells, CulturedFree RadicalsHumansPolyethylene GlycolsRatsRats, TransgenicReactive Oxygen SpeciesAcrylatesFree RadicalsPolyethylene GlycolsReactive Oxygen Speciesbiomaterialsdrug deliveryFree radicalsPEGDApolymerisation

Identifiers

PMID30782037
PMCPMC6682444

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.